Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 409306, BI 425809 and Lamotrigine for Ketamine-Induced Cognitive Deficits
NCT04602221Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2020
- Primary completion
- Aug 2022
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of osoresnontrine and iclepertin in schizophrenia (18 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Paired Associate Learning Total Errors Adjusted (PALTEA28). Started Dec 2020; status: completed.
02
Drugs
osoresnontrineiclepertin
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT04602221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04602221.